news, health,
The Therapeutic Goods Administration is investigating the death of a woman who reportedly developed blood clots after receiving a COVID-19 vaccine. The Daily Mail reported a 48-year-old NSW woman received the vaccine last Friday, developed major blood clots the next day and died on Wednesday. It is not known which vaccine she received, nor if her symptoms were linked to the vaccine. The Canberra Times understands the death is being investigated by the TGA. NSW Health said it doesn’t “speculate” on individual cases, “but the death of anyone is always a tragedy and our condolences are with the family and loved ones of the person who has passed away”. The TGA is responsible for regulating the COVID-19 vaccines. “Monitoring involves detecting and responding to any emerging safety concerns related to COVID-19 vaccines, particularly any adverse events following immunisation,” the NSW Health statement said. “An adverse event following immunisation is any untoward medical event that occurs after a vaccination has been given, which may be related to the vaccine. “A conclusion regarding a causal relationship with the vaccine is not necessary to suspect or report an adverse event. “Many conditions can arise during normal life, whether or not a vaccine is administered, but it remains important to report any new serious or unexpected events so that safety can be appropriately monitored. “Anyone concerned that they are experiencing a serious adverse event following vaccination should see their health care provider in the first instance or dial 000 in an emergency.” The government issued new advice last week that the AstraZeneca vaccine was not recommended for people under 50 unless “the benefit outweighed the risk” of a rare but serious blood clot syndrome. “At the moment, it seems to be around 4 to 6 per [1] million doses of vaccine,” chief medical officer Paul Kelly said last week. “The … recommendation is people that have had their first dose of AstraZeneca without any serious adverse effects can safely be given their second dose. This includes adults under the age of 50. “People who have had blood clots associated with low platelet levels after their first dose of COVID-19 AstraZeneca [vaccine] should not be given the second dose.” Our journalists work hard to provide local, up-to-date news to the community. This is how you can continue to access our trusted content:
/images/transform/v1/crop/frm/pMXRnDj3SUU44AkPpn97sC/5e231a4d-120d-4e5e-98eb-e88598a9bd0e.jpg/r3_307_5998_3694_w1200_h678_fmax.jpg
The Therapeutic Goods Administration is investigating the death of a woman who reportedly developed blood clots after receiving a COVID-19 vaccine.
The Daily Mail reported a 48-year-old NSW woman received the vaccine last Friday, developed major blood clots the next day and died on Wednesday. It is not known which vaccine she received, nor if her symptoms were linked to the vaccine.
The Canberra Times understands the death is being investigated by the TGA.
NSW Health said it doesn’t “speculate” on individual cases, “but the death of anyone is always a tragedy and our condolences are with the family and loved ones of the person who has passed away”.
The TGA is responsible for regulating the COVID-19 vaccines.
“Monitoring involves detecting and responding to any emerging safety concerns related to COVID-19 vaccines, particularly any adverse events following immunisation,” the NSW Health statement said.
“An adverse event following immunisation is any untoward medical event that occurs after a vaccination has been given, which may be related to the vaccine.
“A conclusion regarding a causal relationship with the vaccine is not necessary to suspect or report an adverse event.
“Many conditions can arise during normal life, whether or not a vaccine is administered, but it remains important to report any new serious or unexpected events so that safety can be appropriately monitored.
“Anyone concerned that they are experiencing a serious adverse event following vaccination should see their health care provider in the first instance or dial 000 in an emergency.”
“At the moment, it seems to be around 4 to 6 per [1] million doses of vaccine,” chief medical officer Paul Kelly said last week.
“The … recommendation is people that have had their first dose of AstraZeneca without any serious adverse effects can safely be given their second dose. This includes adults under the age of 50.
“People who have had blood clots associated with low platelet levels after their first dose of COVID-19 AstraZeneca [vaccine] should not be given the second dose.”
Our journalists work hard to provide local, up-to-date news to the community. This is how you can continue to access our trusted content:
